Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin
NCT05360953 · Charite University, Berlin, Germany · PHASE2 · suspended · last registry update 2025-08-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Early termination due to recruitment issues” | – | Registry record, Charite University, Berlin, Germany |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-05Results posted on the registry: Bausch & Lomb Incorporated, a drug against ADRA2A (NCT04840563)
- 2026-06-09Results posted on the registry: Johns Hopkins University, Lofexidine + Placebo (NCT04325659)
- 2026-05-22Results posted on the registry: Johnson & Johnson Vision Care, Inc., a drug against ADRA2A (NCT06749496)
- 2026-04-22Results posted on the registry: Beaver-Visitec International, Inc., a drug against ADRA2A (NCT06399211)
- 2026-04-14Results posted on the registry: University of Michigan, Carbidopa 25 mg + Carbidopa-Levodopa 25/100 mg (NCT06587217)
- 2026-03-19Also stopped (withdrawn): Centre hospitalier de l'Université de Montréal (CHUM), a drug against ADRA2A (NCT05119270)
- 2025-12-23Phase 3 first posted: Ain Shams University, Balanced anesthesia + Lidocaine spray (NCT07299630)
- 2025-12-11Also stopped (terminated): Hopital Charles Nicolle, Ephedrine (6 mg boluses) + Norepinephrine (10 µg boluses) (NCT07259655)
- 2025-09-16Also stopped (withdrawn): Alcon Research, a drug against ADRA2A (NCT06592521)
- 2025-09-03Phase 3 first posted: University Hospital Tuebingen, LECIG (levodopa, carbidopa, entacapone intestinal gel) + Best oral medication (NCT07151378)
- 2025-08-01Also stopped (withdrawn): USWM, LLC (dba US WorldMeds), LUCEMYRA (lofexidine) tablets (NCT06711640)
- 2025-07-23Also stopped (withdrawn): Walter Reed Army Medical Center, a drug against ADRA2A (NCT00412295)
- 2025-07-18Results posted on the registry: University of Michigan, carbidopa/levodopa, as prescribed by treating physician (NCT04821830)
- 2025-07-17Results posted on the registry: Laboratorios Sophia S.A de C.V., Naphazoline / Hypromellose Ophthalmic (NCT05470868)
- 2025-07-16Results posted on the registry: Laboratorios Sophia S.A de C.V., Nanodrop® + Systane Balance (NCT04111965)
- 2025-06-17Results posted on the registry: University of Michigan, Carbidopa 25 mg + Carbidopa-Levodopa 25/100 mg (NCT06219915)
- 2025-06-13Phase 3 first posted: Universitas Indonesia, Standard General Anesthesia Induction Using Propofol, Fentanyl and Midazolam (NCT07019805)
- 2025-03-20Phase 3 first posted: Jagiellonian University, noradrenaline infusion for management blood pressure + standard blood pressure management (NCT06885268)
- 2025-02-07Results posted on the registry: Medical University of South Carolina, Lofexidine + Placebo (NCT03718065)
- 2025-01-30Phase 3 first posted: Shaheed Mohtarma Benazir Bhutto Institue of Trauma, 0.1% xylometazoline nasal drops + Adrenaline nasal pack (NCT06801522)
- 2025-01-29Results posted on the registry: Beaver-Visitec International, Inc., a drug against ADRA2A (NCT04176965)
- 2024-11-19Results posted on the registry: OnPoint Vision Inc, a drug against ADRA2A (NCT04984590)
- 2024-10-30Results posted on the registry: Alcon Research, a drug against ADRA2A (NCT05481125)
- 2024-10-21Results posted on the registry: USWM, LLC (dba US WorldMeds), Lofexidine + Placebo (NCT04070157)
- 2024-10-21Also stopped (terminated): USWM, LLC (dba US WorldMeds), Lofexidine + Placebo (NCT04070157)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision